Collectively, these findings demonstrate that PI3K/Akt/mTOR pathway dysregulation in uterine tumors results from complex interactions between genetic alterations, hormonal influences, and notably, emerging epigenetic mechanisms that represent novel regulatory layers, establishing it as a critical hub for therapeutic intervention. The gene discussed is AKT1; the disease is tumor of uterus.